LOGIN  |  REGISTER
Terns Pharmaceuticals

OptimizeRx to Participate in Upcoming Investor Conferences

November 18, 2024 | Last Trade: US$5.40 0.03 -0.55

WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences: 

  • 13th Annual ROTH Technology Conference, New York City, November 19th – 20th, 2024
  • Canaccord Genuity’s 2024 CG MedTech, Diagnostics and Digital Health & Services Forum, New York City, November 21st, 2024

Conference Details: 

13th Annual ROTH Technology Conference
Date: Tuesday, November 19th – Wednesday 20th
Format:1x1 Meetings
Location:The Hard Rock Hotel, New York City

Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum
Date: Thursday, November 21st
Format:1x1 Meetings
Location:The Westin NY Grand Central, New York City

To request a meeting or for more details about the conferences please reach out to your institutional contact or email.

About OptimizeRx 

OptimizeRx provides best-in-class health technology that enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. Connecting over 2 million U.S. healthcare providers and millions of their patients through an intelligent technology platform embedded within a proprietary digital point-of-care network, as well as mass digital communication channels, OptimizeRx helps life sciences organizations engage and support their customers.

For more information, follow the Company on X, LinkedIn or visit www.optimizerx.com.  

OptimizeRx Contact  
Andy D’Silva, SVP Corporate Finance 
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Investor Relations Contact 
Ashley Robinson 
LifeSci Advisors, LLC 
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Recursion

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page